{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-157458","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.229386+00:00","generated_at":"2026-06-01T05:45:43.049672+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Sarepta increases incentive plan shares by 500,000; all director nominees elected at annual meeting","bullets":["Board approved amendment to 2024 Employment Commencement Incentive Plan, increasing share reserve by 500,000 to 6,185,308 shares.","At June 6 annual meeting, all four Class I director nominees (Douglas Ingram, Hans Wigzell, Kathryn Boor, Michael Chambers) were elected.","Advisory say-on-pay proposal passed with approximately 63.6 million votes for and 9.0 million against.","Stockholders ratified KPMG as independent auditor for 2024; approximately 77.1 million votes in favor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-157458","json":"https://secwatch.observer/filing/0001193125-24-157458.json","markdown":"https://secwatch.observer/filing/0001193125-24-157458.md","text":"https://secwatch.observer/filing/0001193125-24-157458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312524157458/0001193125-24-157458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312524157458/d810236d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:45:43.049672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}